MedTrace Logo

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

NCT00078832 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3864

Last updated 2021-10-06

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Anastrozole may be effective in preventing breast cancer.

PURPOSE: This randomized clinical trial is studying how well anastrozole works in preventing breast cancer in postmenopausal women who are at increased risk for the disease.

Conditions

Interventions

DRUG

anastrozole

aromatase inhibitor

DRUG

placebo

Arimidex placebo

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Jack Cuzick, PhD · Queen Mary University of London

  • Anthony Howell · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2013-12-31
Completion
2021-05-31

Countries

  • Australia
  • Belgium
  • Chile
  • Denmark
  • Finland
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Malta
  • Portugal
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078832 on ClinicalTrials.gov